The simple test could have a major impact on pre-eclampsia rates globally.
Currently 5-8% of pregnancies are affected by the condition.
The Congo Red Dot (CRD) diagnostic test was trialled by 346 pregnant women in the labour and delivery triage unit, at OSU Wexner Medical Center in the US.
The test requires a sample of urine from the pregnant woman to diagnose pre-eclampsia.
Trained nurses analysed the results at the patient’s bedside, before a final clinical diagnosis was made.
Results from the research showed that the CRD diagnostic test is 86% effective – more effective than any other biochemical tests.
Speaking to Wexner Medical, first author of the pre-eclampsia test research and Fellow in the division of Maternal-Fetal Medicine, Dr Kara Rood said: “This is the first clinical study using the point-of-care, paper-based Congo Red Dot diagnostic test, and the mechanism proved superior in establishing or ruling out a diagnosis of preeclampsia.”
89% of the pregnant women who trialled the test had a clinical diagnosis of pre-eclampsia, with 79% of these women having a medically indicated pre-term birth following diagnosis.
Researchers presented the CRD test and their findings at the Society for Maternal-Fetal Medicine’s annual pregnancy meeting in Atlanta, Georgia.
Keep up to date with the latest news from MIDIRS by signing up to our e-newsletter. Sign-up